Study item | Range, total number of studies or description |
Country | USA: n=24 Denmark: n=5 Taiwan: n=4 China: n=1 France: n=1 Scotland: n=1 Sweden: n=1 Spain: n=1 UK: n=1 |
NOAC included in included studies | Dabigatran: n=39 Rivaroxaban: n=39 Apixaban: n=26 Edoxaban: n=1 |
Most prescribed NOAC in included studies per country | Dabigatran: Denmark Rivaroxaban: USA, UK, China, Scotland and Taiwan Apixaban: In none of the included studies Edoxaban: In none of the included studies About equal*: France, Spain, Sweden |
Baseline characteristics | Mean age, years: 65–84 % males: 39–73 Mean CHA2DS2-VASc: 2.1–4.9 |
Primary study outcomes | Effectiveness outcomes:
Safety outcomes:
|
Statistical approaches | PS matching: n=18 IPTW: n=8 PS stratification: n=1 Cox PH regression model: n=10 Unadjusted analyses: n=2 |
Sample size | n=698–265 583 |
Study results | Of the 26 studies in which apixaban, rivaroxaban and dabigatran were included:
|
*About equal distribution between dabigatran, rivaroxaban and apixaban. Edoxaban is not included in these studies.
CHA2DS2-Vasc, Congestive heart failure, Hypertension, Age ≥75 years, Diabetes Mellitus, Prior Stroke or TIA or thromboembolism, Vascular disease, Age 65–74 years, Sex; NOACs, non-vitamin K antagonist oral anticoagulants.